Jupiter Neurosciences Inc - Announces Strategic Initiative for Glp-1 Users

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Jupiter Neurosciences to Present at DealFlow Discovery Conference in Atlantic City

Jupiter Neurosciences Secures $1.86 Million Second Tranche Financing from Yorkville

Jupiter Neurosciences Inc. Held Annual Shareholder Meeting

Jupiter Neurosciences to Present at NobleCon21 Emerging Growth Conference

BRIEF-Jupiter Neurosciences Files Rospectus Related To Resale Of Up To 10 Million Shares Of Our Common Stock By Selling Stockholder

Jupiter Neurosciences Inc - Files Rospectus Related to Resale of up to 10 Mln Shares of Our Common Stock by Selling Stockholder

Jupiter Neurosciences Issues Amended SEC Filing

Jupiter Neurosciences price target lowered to $25 from $30 at Greenridge

Jupiter receives FDA clearance of IND application to initiate Phase 2 trial

BRIEF-Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL in Parkinson’s Disease

Jupiter Neurosciences Inc - Expects Trial Enrollment to Begin in Early 2026

Jupiter Neurosciences Inc - Proceeds to Support Phase 2 Parkinson's Trial and Nugevia Growth

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Jupiter Neurosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting

Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador

Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience